News

NIH-developed dengue vaccine protects all patients in challenge study

As Sanofi works to gain traction for the launch of its world-first dengue vaccine, a potential competitor may be building its case. This week, the National Institutes of Health announced that a candidate developed by scientists there posted "very encouraging" results, according to the team's lead scientist.

Valneva scores $42M supply contract with DOD

Valneva currently markets Ixiaro, a Japanese encephalitis vaccine and Dukoral, the cholera vaccine it acquired from Johnson & Johnson in 2015. Now, the Lyon, France-based vaccine maker is building on its relationship with the U.S. Department of Defense with a new $42 million supply contract for Ixiaro.

Health agencies inform on Zika vaccine timeline

Multiple public health authorities have given insight to the timing of Zika vaccine development, with the WHO now stating that any vaccine may be too late for the current outbreak, a similar situation to the one the world experienced in the Ebola epidemic.

Analyst: Mitsubishi Tanabe's tobacco-based flu jab could have 'significant impact' on market

Following Mitsubishi Tanabe's announcement that its tobacco-based flu vaccine could hit the market by 2018 or 2019, a GlobalData analyst has lauded the Japanese company's candidate as poised to "take over" the flu vaccine market from traditional egg-based vaccines.

Journal walks back 'seriously flawed' study critical of Merck's Gardasil

Citing "seriously flawed" methodology and "unjustified" claims, the journal Vaccine has permanently withdrawn a previously published study critical of Merck's Gardasil.

Duke, NIAID track HIV evolution with eyes on creating a vaccine

A team led by the Duke Human Vaccine Institute and the National Institute of Allergy and Infectious Diseases has tracked the evolution of HIV and the body's corresponding immune response, hoping now to turn the knowledge gained into an experimental vaccine.

South Korea's Green Cross to supply Americas with flu vaccine in $32M deal

South Korea's Green Cross announced a $32 million deal on Wednesday to supply its flu vaccines to the Pan American Health Organization, the WHO's regional office in the Americas.

Vaxart, Immunovaccine, Mayo Clinic jump onto Zika vaccine bandwagon

Widening the field further, Vaxart, Immunovaccine and Mayo Clinic are joining a slew of biotechs and pharmas either exploring or embarking on Zika vaccine development.

Sanofi digs into details on hastened Zika effort

Just last month, Sanofi became the first Big Pharma player to enter the Zika vaccine R&D space as its peers calculated their responses and weighed their options. Now, the French pharma is taking it a step further, outlining its plans to devote dozens of scientists to the field in a move aimed at expediting its vaccine development.

U.K. rejects petition demanding meningitis B vaccine for all children

The U.K. rolled out its meningitis B vaccination program for babies in September, but a petition demanding that it be expanded for all children quickly gathered steam. The Department of Health rejected the petition on Wednesday, saying that offering the jab to all children would not be cost-effective.

U.S. Army, GSK's P. vivax malaria vaccine fails to protect in early trial

A vaccine developed in collaboration between GlaxoSmithKline and the U.S. Army failed to protect subjects in an early trial against the world's most prevalent malaria parasite. Researchers will press forward, however, saying the knowledge gained may assist future development.

Seqirus to build new U.K. manufacturing outpost

Seqirus--the world's second largest flu vaccine player formed CSL's purchase of Novartis flu vaccines--this week said it's expanding in the U.K. It'll spend £15.3 million ($21.3 million) on a new flu vaccine manufacturing site in Speke, an announcement the company made as it opened a £6.8 million warehouse there.

Novavax explores Zika vaccine R&D effort as virus continues to spread

Vaccine companies and research organizations worldwide continue to race against Zika, with a new entrant emerging in Novavax. The biotech announced it's conducting preliminary Zika research in a week that saw several other developments in the field.

New South Korean study could help direct MERS vaccine development

Several players are working on vaccines for Middle East respiratory syndrome (MERS), including the NIH and tandem GeneOne and Inovio, both of which had successful animal trials for their candidates. Now, a new study out of South Korea--showing that the MERS virus mutated during the outbreak--could help vaccine developers pinpoint their target on the surface of the MERS virus.

Brazil funds dengue vaccine PhIII, report says

Brazil officials signed off this week on funding for a late-stage dengue vaccine trial, adding another twist to the global dengue vaccine competition amid the launch of the first approved jab.

Researchers create first 3-D 'map' of malaria parasite protein

Scientists have created the first 3-D "map" of a protein used by malaria parasites to invade human blood cells. This could lead to the development of a vaccine that could attack the most widespread species of the parasite.

Mitsubishi Tanabe's tobacco-based flu jab to enter late-stage trials this year

With flu season in full swing, Mitsubishi Tanabe has its eyes on the horizon as it aims to get its quick-to-produce, tobacco-based flu vaccine on the market by 2018 or 2019. Nikkei Asian Review reported on Tuesday that the Osaka-based company has "all but finished" safety and efficacy trials of the vaccine in the U.S. and Canada and plans to run late-stage trials by the end of the year.

Inovio says Zika vaccine shows promise in mice and shoots for human trial by year-end

While it doesn't yet market any products, Inovio continues to be the Zika vaccine front-runner, reporting that its experimental jab induced a "robust and durable" immune response in mice.

Philippines' immunization program for Sanofi's Dengvaxia set to start in April

Sanofi's Dengvaxia is set for a wide rollout in the Philippines, making the endemic nation the first to implement an immunization campaign utilizing the dengue fever vaccine.

HPV rates dive following vaccine introduction, national study says

Merck, GlaxoSmithKline and public health officials in the United States have some big new numbers to tout to promote HPV vaccination. On Monday, a group of federal researchers said that since the introduction of Gardasil in 2006, HPV infection rates in teenage girls have fallen by nearly two-thirds.